Protalix, an Israeli biopharmaceutical company located outside of the northern city of Carmiel, said Saturday that it has the resources to produce the experimental Ebola vaccine, ZMapp, which has recently run out.
In an interview with Channel 2, Protalix’s Dr. Yossi Shaaltiel, the executive vice president of research and development said: “Today our production capacity exceeds our needs, and we would certainly be happy to have the company producing the Ebola drug have us produce the drug for them. We would know how to do it effectively, in large quantities, and in a relatively short period of time.”
Read more at The Times of Israel
Related: Pfizer Prescription Medication for Gaucher Disease Receives OU Kosher Certification
The words of this author reflect his/her own opinions and do not necessarily represent the official position of the Orthodox Union.